Apr 27, 2020   SOURCE: PR NewsWire

2020 Pipeline Guide for Influenza A Virus, H1N1, Segmented by Stage of Development, Drug Target, MoA, RoA and Molecule Type

DUBLIN, April 27, 2020 /PRNewswire/ -- The "Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This pipeline guide provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The pipeline guide also reviews the key players involved in the therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 7, 9, 4, 43, 7 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 4, 2, 13 and 2 molecules, respectively.

The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope of the report:

    --  The pipeline guide provides a snapshot of the global therapeutic
        landscape for Influenza A Virus, H1N1.
    --  The pipeline guide reviews pipeline therapeutics for Influenza A Virus,
        H1N1 by companies and universities/research institutes based on
        information derived from company and industry-specific sources.
    --  The pipeline guide covers pipeline products based on several stages of
        development ranging from pre-registration till discovery and undisclosed
        stages.
    --  The pipeline guide features descriptive drug profiles for the pipeline
        products which comprise, product description, descriptive licensing and
        collaboration details, R&D brief, MoA & other developmental activities.
    --  The pipeline guide reviews key companies involved in Influenza A Virus,
        H1N1 therapeutics and enlists all their major and minor projects.
    --  The pipeline guide evaluates Influenza A Virus, H1N1 therapeutics based
        on mechanism of action (MoA), drug target, route of administration (RoA)
        and molecule type.
    --  The pipeline guide encapsulates all the dormant and discontinued
        pipeline projects.

    --  The pipeline guide reviews latest news related to pipeline therapeutics
        for Influenza A Virus, H1N1.

Key benefits:

    --  Procure strategically important competitor information, analysis, and
        insights to formulate effective R&D strategies.
    --  Recognize emerging players with potentially strong product portfolio and
        create effective counter-strategies to gain competitive advantage.
    --  Find and recognize significant and varied types of therapeutics under
        development for Influenza A Virus, H1N1.
    --  Classify potential new clients or partners in the target demographic.
    --  Develop tactical initiatives by understanding the focus areas of leading
        companies.
    --  Plan mergers and acquisitions meritoriously by identifying key players
        and it's most promising pipeline therapeutics.
    --  Formulate corrective measures for pipeline projects by understanding
        Influenza A Virus, H1N1 pipeline depth and focus of Indication
        therapeutics.
    --  Develop and design in-licensing and out-licensing strategies by
        identifying prospective partners with the most attractive projects to
        enhance and expand business potential and scope.
    --  Adjust the therapeutic portfolio by recognizing discontinued projects
        and understand from the know-how what drove them from pipeline.


Key Topics Covered

    --  Influenza A Virus, H1N1 Subtype Infections - Overview
    --  Influenza A Virus, H1N1 Subtype Infections - Therapeutics Development
    --  Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment
    --  Influenza A Virus, H1N1 Subtype Infections - Companies Involved in
        Therapeutics Development
    --  Influenza A Virus, H1N1 Subtype Infections - Drug Profiles
    --  Influenza A Virus, H1N1 Subtype Infections - Dormant Projects
    --  Influenza A Virus, H1N1 Subtype Infections - Discontinued Products
    --  Influenza A Virus, H1N1 Subtype Infections - Product Development
        Milestones

Companies Mentioned 

    --  AbbVie Inc
    --  Abzyme Therapeutics LLC
    --  Adimmune Corp
    --  Akshaya Bio Inc
    --  Alla Chem LLC
    --  Allergy Therapeutics Plc
    --  Altimmune Inc
    --  Ansun Biopharma Inc
    --  Asavi Llc
    --  AstraZeneca Plc
    --  Beijing Minhai Biotechnology Co Ltd
    --  BlueWillow Biologics Inc
    --  Brandenburg Antiinfektiva GmbH
    --  BunyaVax BV
    --  CEL-SCI Corp
    --  Changchun Bcht Biotechnology Co Ltd
    --  Chicago Biosolutions Inc
    --  CHO Pharma Inc
    --  Cidara Therapeutics Inc
    --  Cilian AG
    --  Cocrystal Pharma Inc
    --  Curevac AG
    --  Cytocom Inc
    --  Dnarx LLC
    --  Emergent BioSolutions Inc
    --  Ena Therapeutics Pty Ltd
    --  EpiVax Inc
    --  Etubics Corp
    --  FluGen Inc
    --  Gamma Vaccines Pty Ltd
    --  Genentech Inc
    --  GlaxoSmithKline Plc
    --  Greffex Inc
    --  i2 Pharmaceuticals Inc
    --  ILiAD Biotechnologies LLC
    --  Imutex Ltd
    --  Inovio Pharmaceuticals Inc
    --  InvVax Inc
    --  Jiangsu Kanion Pharmaceutical Co Ltd
    --  Johnson & Johnson
    --  Mayly Life Sciences
    --  Medicago Inc
    --  Microbiotix Inc
    --  NanoViricides Inc
    --  New Amsterdam Sciences Inc
    --  Novavax Inc
    --  PeptiDream Inc
    --  Pneumagen Ltd
    --  Recce Ltd
    --  Sanofi Pasteur SA
    --  Sciogen Inc
    --  Seqirus Ltd
    --  Serum Institute of India Ltd
    --  TechnoVax Inc
    --  Tiba Biotech LLC
    --  Touchlight Genetics Ltd
    --  UMN Pharma Inc
    --  Vaccibody AS
    --  Vacthera BioTech GmbH
    --  Vaxart Inc
    --  Vaxxas Pty Ltd
    --  Viramatix Sdn Bhd
    --  Virion Biotherapeutics
    --  Vironova Medical AB
    --  Virvio Inc
    --  Visterra Inc
    --  Vivaldi Biosciences Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/y6po2l

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/2020-pipeline-guide-for-influenza-a-virus-h1n1-segmented-by-stage-of-development-drug-target-moa-roa-and-molecule-type-301047705.html

SOURCE Research and Markets